semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Normal Physiology fMRI Participants will be 272 healthy volunteers drawn from the population in the NIH clinical research volunteer program. Healthy Right-handed Ages 18-70 (inclusive) Have completed high school or college in an English speaking country. All participants must have had a neurological examination by a NINDS physician within the last two years. All participants in the fMRI experiments must also have had a clinical MRI within the last year  Individuals with conditions that could pose a risk relating to the safety of the MRI procedure will be excluded from the protocol such as: Those with ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body. Those with an implanted cardiac pacemaker or auto-defibrillator. Those with an insulin pump. Those with an irremovable body piercing. Pregnant women Individuals with conditions that could pose a risk relating to the safety of the TMS procedure will be excluded from the protocol such as Those with significant abnormality on neurological examination Those with metal in the cranial cavity or eye, e.g. aneurysm clip, implanted neural stimulator, cochlear implant, ocular foreign body Those with an implanted cardiac pacemaker or auto-defibrillator Those with an insulin pump Pregnant women Individuals with conditions that could compromise our interpretation of the TBS and fMRI results will be excluded such as Those with significant abnormality on neurological examination Those who have a significant psychiatric illness or have a history of psychiatric illness Those using medication affecting the DA system, such as phenothiazine antihistamines (promethazine), antiemetics or decongestants within the last month
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Parkinson's Disease Parkinsonism Able to give informed consent prior to study 2. Male or Female with Diagnostic of Parkinson's disease or neurodegenerative disorder undergoing a neurosurgical procedure 3. Age 35 to 85 years old 4. Parkinson's disease not due to trauma, infection, brain tumor, cerebrovascular disease 5. Hoehn and Yahr Stage III or IV 6. Parkinson's disease observed in the absence of Oculomotor palsy Cerebellar sign Orthostatic hypotension (drop greater than 20mmHg in mean pressure) Pyramidal sign Amyotrophy 7. Good general health or stable medical condition well controlled, without contraindications to anesthesia  Patients with severe dementia and brain atrophy on MRI 2. Patients with severe hypertension; renal, liver, cardiac or other major organ disease; coagulopathy; cancer; other significant systemic illnesses; hepatitis, HIV 3. Patients older than 85 or younger than 35 4. Patients who withhold informed consent 5. Patients with a history of alcohol or drug abuse 6. Sexually active women of childbearing potential without adequate form of birth control 7. Evidence of abnormal coagulation or anticoagulant therapy 8. Pregnancy or lactation 9. History of seizure disorders or current use of antiepileptic medication 10. Severe cognitive impairment 11. Clinically significant laboratory abnormality
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Primary Hypercholesterolemia Mixed Dyslipidemia Has a history of primary hypercholesterolemia or mixed dyslipidemia and meets LDL-C and triglyceride criteria Is high risk coronary heart disease (CHD) and has LDL-C ≤190 mg/dL (≤4.91 mmol/L) Is not high risk CHD and has LDL-C ≤240 mg/dL (≤6.21 mmol/L)  Is pregnant or breast-feeding, or expecting to conceive or donate eggs or sperm during the study Has a history of malignancy within ≤5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer Consumes more than 3 alcoholic drinks per day (14 per week) Is a high risk CHD patient on lipid modifying therapy (LMT) Is on any LMT with equivalent or greater LDL-C-lowering efficacy than simvastatin 40 mg Has Type 1 or Type 2 diabetes mellitus that is poorly controlled, or on statin therapy Currently engages in vigorous exercise or is on an aggressive diet regimen Has uncontrolled endocrine or metabolic disease, uncontrolled gout, kidney or hepatic disease, heart failure, recent peptic ulcer disease, hypersensitivity or allergic reaction to niacin or simvastatin, recent heart attack, stroke or heart surgery Is human immunodeficiency virus (HIV) positive Has taken niacin >50 mg/day, bile-acid sequestrants, 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitors, ezetimibe, Cholestin™ [red yeast rice] and other red yeast products within 6 weeks, or fibrates within 8 weeks of randomization visit (Visit 3). Note: Fish oils, phytosterol margarines and other non-prescribed therapies are allowed provided participant has been on a stable dose for 6 weeks prior to Visit 2 and agrees to remain on this dose for the duration of the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-90.0,  Parkinson Disease Subjects will be diagnosed with Parkinson Disease (PD) by the UK Brain Bank criteria Subjects will have to be at least stage 2 on the Hoehn and Yahr staging system of PD and have a history of at least 1 fall or near fall in the last 6 months Subjects must have a stable medication regimen All subjects will be over the age of 40 in an attempt to inherited forms of parkinsonism Serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and EKG are within normal limits (results obtained from primary care physician and dated within the past 6 months or obtained at screening visit)  Hoehn and Yahr stage V subjects Subjects with a history of major psychiatric disorder, deep brain stimulation surgery, recent cerebral trauma, cardiac arrhythmia, or renal insufficiency A cardiovascular procedure in the last 5 years (eg, percutaneous transluminal coronary angioplasty) or have cardiovascular instability (including myocardial infarction or unstable angina). Other cardiovascular exclusions uncontrolled hypertension, significant neurological sequelae of cerebrovascular disease, peripheral vascular disease with prior amputation, or severe congestive heart failure (New York Heart Association class III or IV) Concurrent treatment with any MAOIs, bupropion (Wellbutrin), or nicotine patches Dementia or other psychiatric illness that prevents the patient from giving informed consent (Folstein Mini Mental Status Exam score less than 25) Concurrent treatment with trihexyphenidyl (Artane) or benztropine mesylate (Cogentin) Significant degree of dysphagia, by history Legal incapacity or limited legal capacity Presence of severe renal disease (BUN 50% greater than normal or creatinine clearance <60 mL/min) or hepatic disease Abnormal creatine kinase and/or platelet count in the past 6 months (as determined by lab reports obtained from primary care physicians or conducted at baseline)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Parkinson's Disease Subjects enrolled in this study must meet the following 1. Subject has signed an informed consent. 2. Subject has been diagnosed, by a neurologist, with idiopathic Parkinson's disease. 3. Subject is a candidate for surgery. 4. Subject is 18 to 80 years of age. 5. Subject has a history of improvement of Parkinson's symptoms as a direct result of administering l-dopa to the subject with at least a 25% improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score or subject has been diagnosed with tremor-dominant Parkinson's disease. 6. Subject should be stable on anti-Parkinson's disease medication for at least one month prior to study enrollment  Subjects will be excluded from the study if they meet any of the following 1. Subject has any major illness or medical condition that in the opinion of the physician would interfere with participation in the study. 2. Subject has non-treated clinically significant depression or any other significant psychiatric co-morbidities. 3. Subject has any condition requiring repeated MRI scans; 4. Subject has any condition requiring diathermy; 5. Subject is on anticoagulant medications and is unable to interrupt for time of procedure. 6. Subject has a history of cranial surgery. 7. Subject has dementia that interferes with their ability to co-operate or comply with study requirements or comprehend the Informed Consent as determined by the investigator. 8. Subject abuses drugs or alcohol. 9. Subject has a history of seizure 10. Subject has confirmation of diagnosis of a terminal illness associated with survival <12 months. 11. Female that is lactating or of childbearing potential with positive urine pregnancy test or not using adequate birth control. 12. Subject has participated in a drug, device or biological trial within the preceding 30 days
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Clinical diagnosis of Parkinson's disease  Inability to follow the required clinical instruction Subjects with cognitive impairments that would prohibit them from properly using the Kinesia HomeView system Subjects without the cognitive ability to respond to researchers and let them know when any parameters of the study may become uncomfortable Subjects found on examination by our clinicians to have any physical limitations which would be counter productive to participation in this study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Parkinson's Disease Diagnosis of Idiopathic Parkinson's disease  Outside of the age range
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Alzheimer's Disease Amyotrophic Lateral Sclerosis (ALS) Multiple Sclerosis (MS) Parkinson's Disease Stroke Traumatic Brain Injury All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's Disease, Stroke, and Traumatic Brain Injury The population for this study will be 18 years and over
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Shoulder Arthroscopy subacromial impingement disease scheduled for an elective arthroscopic surgery  liver disease renal impairment psychiatric disorder alcohol abuse obesity (a body mass index of > 35 kg/m2) allergies to the drugs used in the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 32.0-87.0,  Amyotrophic Lateral Sclerosis Alzheimer Disease Parkinson's Disease Clinical diagnosis of Alzheimer's Disease, Parkinson's disease and amyotrophic lateral sclerosis
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 35.0-85.0,  Parkinson's Disease Idiopathic Parkinson's disease Treatment with carbidopa/levodopa Motor fluctuations  Dementia Hallucinations Age greater than 85
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease years and older, both males and females, all races and all ethnicities Idiopathic Parkinson's disease diagnosed using United Kingdom Parkinson's Disease Society brain bank diagnostic Mild to moderate disease severity (Stage 2 to 3 on the Modified Hoehn and Yahr scale) Stable medication regimen for a minimum of 1 month before testing Ability to ambulate independently without using a walking aid Ability to give informed consent  Prior enrollment in a dancing class during the last 6 months Presence of another neurological or medical disorder likely to affect gait or causing frequent falls (rheumatologic/orthopedic disease, stroke, myelopathy, severe neuropathy) Significant cognitive decline (MMSE ≤ 24) Visual deficit Hearing deficit that impairs music perception Psychotic symptoms Symptomatic heart disease Depression associated with suicidal ideation
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cerebrovascular Accident Stroke, Acute Cerebral Stroke All patients of both gender from 18 years of age with a diagnosis of Fabry disease with the mutation N215S Written informed consent from patient  Patients without a diagnosis of Fabry disease No written informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 25.0-65.0,  Obesity Nonalcoholic Fatty Liver Disease Male 65 years Obesity (BMI > 28 kg/m2, waist/hip ratio > 0,95) Have nonalcoholic fatty liver disease (NAFLD)(intervention group) or do not have NAFLD (control group) May have hypertension and/or hypercholesterolemia Written informed consent  Any other disease than NAFLD (e.g. diabetes, thyroid or parathyroid disease, heart, liver or kidney disease) Present and previous malignancy Alcohol dependency (more than 21 units of alcohol per week) History of smoking Participation in studies with radioactive isotopes within the last six months Hemoglobin under normal range regarding to sex (under 8.3 mmol/l for men)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Parkinson's Disease (exercise arm) Idiopathic Parkinson's disease A stable condition the last 6 months Hoehn and Yahr 2 (Deep Brain Stimulation arm) Patients referred to Deep Brain Stimulation  Cardiovascular disease Conditions that contraindicate physical exercise or the examination